Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial

BACKGROUND AND OBJECTIVE: Avelumab is approved for the treatment of metastatic Merkel cell carcinoma, a rare aggressive skin cancer with a poor prognosis. The aim of this qualitative study embedded in a clinical trial was to explore patient experiences while receiving avelumab. METHODS: All treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Jérémy, Marrel, Alexia, D’Angelo, Sandra P., Burgess, Melissa A., Chmielowski, Bartosz, Fazio, Nicola, Gambichler, Thilo, Grob, Jean-Jacques, Lebbé, Céleste, Robert, Caroline, Russell, Jeffrey, Güzel, Gülseren, Bharmal, Murtuza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340640/
https://www.ncbi.nlm.nih.gov/pubmed/32472503
http://dx.doi.org/10.1007/s40271-020-00428-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340640/
https://www.ncbi.nlm.nih.gov/pubmed/32472503
http://dx.doi.org/10.1007/s40271-020-00428-5

Ejemplares similares